Pioneering a paradigm shift for ‘selective’ neural electrical stimulation
Restoring hand grasping movements in patients with complete tetraplegia will be the first of Neurinnov’s applications using its technology platform.
Mastering selective stimulation is the core of Neurinnov’s business. Its ‘generic’ technology platform can stimulate whichever nerve is required to restore or modulate a function while limiting undesired activation. Mitigating the side-effects that can be induced by a non-selective stimulation is the proof of value.
An embedded ASIC, the key to achieving selective stimulation and the ability to guide the stimulation of a nerve
Casing surrounding the neurostimulator to which electrodes are connected
A controller connected to the implant via an external antenna. The wireless powering of and communication of data with the implanted device will be enabled by wireless transcutaneous energy transfer
Software with advanced interfaces to ease the tuning of the neuroprosthesis. Hand biomechanics are complex and selective stimulation is contra intuitive. The software embeds powerful algorithms that will overcome these issues
An intuitive patient interface that allows the user to control the whole system with discretion, preliminary assessed by patients: the learning curve was short and the efficiency was high.
Our implantable neurostimulator is specifically designed for a population of patients living with a complete tetraplegia who are ineligible for tendon transfer and orthopedic surgery, the only solutions available to date.
Neurinnov’s goal is to provide them with an implant through which they can control a desired hand movement by using one of four modalities to pilot the neurostimulator device. The patient will be able to choose to open a hand via:
Two patients with complete tetraplegia, a condition of paralysis from the shoulders down, were once again able to grasp objects and perform everyday activities, such as holding a can or eating with fork, through the use of a neurostimulation device designed by Neurinnov under the AGILIS study, led by Inria.
A strong caliber of partners is vital to enabling us to stretch our imaginations. Together, we search for new and improved approaches that advances technological developments in neurostimulation to bring real benefits to underserved medical populations.